Dr. Ioannis S. Chatzizisis, MD, PhD

Dr. Chatzizisis practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Chatzizisis' NPI, 1528406097, was assigned on June 6, 2013. Dr. Chatzizisis graduated from Aristotle University of Thessaloniki School of Medicine in 2000. Dr. Chatzizisis holds Florida license ME159593.

Dr. Chatzizisis' primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Chatzizisis' primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Chatzizisis to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chatzizisis practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Chatzizisis' primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Chatzizisis is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Chatzizisis' licenses on file in 3 states: Florida, Nebraska and Massachusetts.

Dmand AI lists angioplasty, cardiac catheterization, chronic hypertension, coronary artery disease, heart valve disorders and high cholesterol among the conditions Dr. Chatzizisis treats.

CMS data shows 307 Medicare services from Dr. Chatzizisis across 11 procedure codes in 2024, for 228 Medicare patients. Medicare paid $26,468 for them.

CMS counts 228 Medicare patients who saw Dr. Chatzizisis in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chatzizisis' median patient age at 71, with 42% women.

In 2024, Dr. Chatzizisis wrote 683 Medicare Part D claims for 117 patients. 76% of them were for generic drugs. CMS names the drug for 635 of them, across 20 drugs with 11 or more claims each, at $135,503 in total drug cost. In 2023, CMS named 369 claims across 14 drugs.

Dr. Chatzizisis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chatzizisis as offering telehealth. CMS counts 23 procedures of coronary angioplasty and stenting by Dr. Chatzizisis, more than 55% of the clinicians it reports for that procedure.

Dmand AI links Dr. Chatzizisis to 1 clinical trial. Conditions studied include Coronary Artery Disease and Coronary Disease.

CMS Open Payments shows 230 general payments to Dr. Chatzizisis from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Boston Scientific Corporation paid the most, $128,056.

Dmand AI lists 24 awards for Dr. Chatzizisis, most recently Bifurcation Person of the Year in 2021. Dr. Chatzizisis serves on Chair elect SCAI Bifurcation Club and European Bifurcation Club.

Dr. Chatzizisis graduated from Aristotle University of Thessaloniki School of Medicine in 2000. Dr. Chatzizisis is a member of ACC, AHA, ASE, ASNC, British Society for Cardiovascular Research, British Society for Cardiovascular Research and ESC Working Group 06 - Coronary Pathophysiology and Microcirculation, ESC Working Group.

Dr. Chatzizisis is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.